UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease.
The UK Kidney Association's updated anaemia guideline gives graded, evidence-based guidance on iron use, iron deficiency without anaemia, anaemia after kidney transplantation and the newer HIF-PHI drugs across non-dialysis CKD, dialysis and transplant patients.
Background
Anaemia is common across chronic kidney disease, including non-dialysis CKD, people on peritoneal dialysis or haemodialysis, and kidney transplant recipients. Iron deficiency and erythropoietin deficiency are the most common causes, especially in people on kidney replacement therapy. UK frameworks, NICE and KDIGO all advocate treating anaemia in CKD.
Key findings
The guideline provides graded practice guidance on the use of iron, comments on iron deficiency without anaemia in CKD, adds information on anaemia management in kidney transplant recipients, and gives guidance on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), which are now in current use. It notes that blood transfusions are infrequently required.
Clinical implications
The update extends anaemia guidance to transplant recipients and to HIF-PHI use, and includes audit and research recommendations to support service evaluation and future evidence generation.
Category
KDIGO
Source
BMC Nephrol
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.